Skip to main content
Elsevier

Pharmacological Targets in Metabolic Diseases

Challenges and Opportunities

  • 1st Edition - September 3, 2025
  • Latest edition
  • Editor: Marcos Roberto de Oliveira
  • Language: English

Pharmacological Targets in Metabolic Diseases: Challenges and Opportunities is a complete reference on possible drug development targets to be leveraged in therapeutic develo… Read more

Description

Pharmacological Targets in Metabolic Diseases: Challenges and Opportunities is a complete reference on possible drug development targets to be leveraged in therapeutic developments. Covering both signaling pathways and specific proteins, the book presents ways to modulate the molecular and cellular alterations observed in metabolic diseases and disorders through the application of new or classical drugs. The comprehensive coverage starts by providing an overview of metabolic diseases and disorders, biological alterations, and pharmacological targets. This section covers targets at both molecular, and subcellular and cellular levels. The next section in the book is focused on pharmaceutical targeting of organs, including a dedicated chapter to the gut-brain axis. Next comes a thorough review of the current advances in metabolic syndrome research. Section VI is focused on inborn errors of metabolism and is followed by a section devoted to natural molecules and their pharmacological potential to treat these conditions. The Editor introduces next a whole section dedicated to the role of the microbiota in metabolic diseases therapeutics. The following sections cover the impact of aging, nanotechnology, the environment, and finally diagnostic techniques in metabolic diseases and disorders. Pharmacological Targets in Metabolic Diseases: Challenges and Opportunities meet the needs of pharmacology researchers looking for a comprehensive and authoritative source of information on possible therapeutic targets to treat these conditions. Research physicians, nutritionists, pharmacists, and biologists can benefit from the detailed information provided at the different levels of targets identified to treat metabolic diseases and conditions.

Key features

  • Covers the most prevalent metabolic diseases and disorders such as metabolic syndrome, diabetes mellitus (types I and II) and dyslipidemia, among others
  • Includes chapters on the microbiome and environmental pollution as they relate to metabolic diseases and conditions
  • Discusses cellular structures like the endoplasmic reticulum and mitochondria as pharmacological targets

Readership

Academic and corporate researchers in Pharmacy, Pharmacology, Biology, and Nutrition.

Table of contents

Part I: Subsection: Overview of metabolic diseases and disorders, biological alterations, and pharmacological targets

Section I: Molecular level

1. Molecular and cellular targets in the management of metabolic diseases and disorders: an overview

2. Pharmaceutical aspects of conventional and recent developments for the treatment of metabolic diseases and disorders

3. NADPH oxidase, obesity and metabolic syndrome: therapeutic opportunity

4. Targeting reactive carbonyls in metabolic disorders

Section II: Subcellular and cellular levels

5. Targeting autophagy in metabolic diseases

6. Endoplasmic reticulum as a pharmacological target in metabolic diseases

7. Pharmacologically targeting caveolae in metabolic diseases

Part II: Subsection: Organs as pharmacological targets in metabolic diseases and disorders


8. The gut-brain axis as a pharmacological target for depressive disorder and Alzheimer’s disease in diabetes {i|mellitus}

9. Cardiomyopathy in metabolic diseases: pharmacological strategies

10. Diabetic kidney disease: treatment and challenges

11. Unraveling the Enigma of Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Therapeutic Horizons

12. Pharmacologic intervention of nonalcoholic steatohepatitis and related cirrhosis

Part III: Subsection: Obesity


13. Pharmacological targets in obesity

14. Adipose tissue and metabolic diseases: a target for prevention and treatment of metabolic diseases

Part IV: Subsection: Metabolic syndrome


15. Metabolic syndrome: pharmacological strategies and challenges

16. Pharmacological targets in metabolic syndrome-related dyslipidemia

17. Plant molecules and metabolic syndrome: therapeutic opportunities

Part V: Subsection: Natural molecules and metabolic diseases and disorders


18. Polyphenols and obesity: molecular targets and therapeutic potential

19. Plant Molecules: Prevention and Management of Diabetes Mellitus

20. Molecular targets in dyslipidemia: therapeutic potential of plant molecules

21. Polyphenols and the control of immunometabolism as a pharmacological target

Part VI: Subsection: Microbiota and metabolic diseases and disorders


22. Microbiota, metabolic disorders and pharmacological opportunities

23. Gut microbiota as a pharmacological target in cardiovascular diseases

24. Plant molecules in obesity and the gut microbiota

25. Microbiota and fatty liver disease: potential candidate for therapeutic intervention

Part VII: Subsection: Nutrition and food interactions


26. Nutrition and Drug Interactions in Metabolic Diseases

Review quotes

“…arranged in a broad, introductory manner initially, and then delves into organ systems and various conditions in the context of potential pharmacological treatment options… The book accomplishes this with its organization into seven parts to cover a wide range of topics. Given the impact of these metabolic disorders on society, this is a worthy topic… [It’s] a great resource for basic scientists and clinicians, to better understand the athophysiology of metabolic disease, the pharmacotherapeutic targets and processes involved in treating these conditions, and what future options and innovations could drive more effective future treatments. Based on the effective organization of this book, this is a worthwhile resource for both scientists and clinicians who are involved and interested in treating various metabolic conditions.”

Review by Keith Lertsburapa, MD (AdventHealth Medical Group), ©Doody's Review Service, 2026.

Product details

  • Edition: 1
  • Latest edition
  • Published: September 3, 2025
  • Language: English

About the editor

MO

Marcos Roberto de Oliveira

Marcos Roberto de Oliveira, PhD earned his bachelor’s degree in Biological Sciences at Federal University of Rio Grande do Sul (UFRGS) in 2005, followed by a master’s and a Ph.D. in Biochemistry from the same institution. He is currently a professor and coordinates research at UFRGS. His research focuses on the neuroprotection mediated by natural molecules and involves studies on mitochondrial physiology, redox biology, bioenergetics, and inflammation in both in vitro and in vivo experimental models.

Affiliations and expertise
Professor, Department of Biochemistry, Federal University of Rio Grande do Sul, Universidade Federal do Rio Grande do Sul (UFRGS), Instituto de Ciências Básicas da Saude (ICBS), Departamento de Bioquímica, Rua Ramiro Barcelos, Brazil

View book on ScienceDirect

Read Pharmacological Targets in Metabolic Diseases on ScienceDirect